Compare HAFC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | SDGR |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | | |
| Employees | N/A | 787 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.9M | 856.7M |
| IPO Year | N/A | N/A |
| Metric | HAFC | SDGR |
|---|---|---|
| Price | $27.23 | $11.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.33 | $24.33 |
| AVG Volume (30 Days) | 315.2K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.65 | $23.91 |
| Revenue Next Year | $7.28 | $19.40 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.25 | $11.15 |
| 52 Week High | $30.20 | $28.47 |
| Indicator | HAFC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 27.77 |
| Support Level | $26.36 | $11.15 |
| Resistance Level | $28.43 | $13.94 |
| Average True Range (ATR) | 0.84 | 0.75 |
| MACD | -0.04 | -0.14 |
| Stochastic Oscillator | 54.04 | 19.08 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.